Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pierre fabre medicament , francúzsko - vinorelbín - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pierre fabre medicament , francúzsko - vinorelbín - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pierre fabre medicament , francúzsko - vinorelbín - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

unimed pharma, spol. s r.o., slovensko - latanoprost - 64 - ophthalmologica

Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastické činidlá - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Slovensko - slovenčina - myHealthbox

bayer ag - suspenzný koncentrát - metribuzin 600 g/l

Slovensko - slovenčina - myHealthbox

bayer ag - suspenzný koncentrát - metribuzin 600 g/l

Slovensko - slovenčina - myHealthbox

bayer ag - suspenzný koncentrát - metribuzin 600 g/l